DK3590942T3 - Hepatitis B-virusoverfladeantigeninhibitor - Google Patents

Hepatitis B-virusoverfladeantigeninhibitor Download PDF

Info

Publication number
DK3590942T3
DK3590942T3 DK18763490.2T DK18763490T DK3590942T3 DK 3590942 T3 DK3590942 T3 DK 3590942T3 DK 18763490 T DK18763490 T DK 18763490T DK 3590942 T3 DK3590942 T3 DK 3590942T3
Authority
DK
Denmark
Prior art keywords
hepatitis
surface antigen
virus surface
antigen inhibitor
inhibitor
Prior art date
Application number
DK18763490.2T
Other languages
English (en)
Inventor
Fei Sun
Jinhua Du
Yanbin Hu
Lili Zhou
Charles Z Ding
Shuhhui Chen
Original Assignee
Fujian Cosunter Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujian Cosunter Pharmaceutical Co Ltd filed Critical Fujian Cosunter Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK3590942T3 publication Critical patent/DK3590942T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK18763490.2T 2017-03-09 2018-03-09 Hepatitis B-virusoverfladeantigeninhibitor DK3590942T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710138275 2017-03-09
PCT/CN2018/078581 WO2018161960A1 (zh) 2017-03-09 2018-03-09 乙型肝炎病毒表面抗原抑制剂

Publications (1)

Publication Number Publication Date
DK3590942T3 true DK3590942T3 (da) 2021-09-06

Family

ID=63447286

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18763490.2T DK3590942T3 (da) 2017-03-09 2018-03-09 Hepatitis B-virusoverfladeantigeninhibitor

Country Status (25)

Country Link
US (1) US11008331B2 (da)
EP (1) EP3590942B1 (da)
JP (1) JP6783424B2 (da)
KR (1) KR102087397B1 (da)
CN (1) CN109071564B (da)
AU (1) AU2018232071B2 (da)
BR (1) BR112019018650B1 (da)
CA (1) CA3055442C (da)
DK (1) DK3590942T3 (da)
EA (1) EA038122B9 (da)
ES (1) ES2879930T3 (da)
HR (1) HRP20211331T1 (da)
HU (1) HUE055170T2 (da)
IL (1) IL269142B (da)
LT (1) LT3590942T (da)
MX (1) MX2019010736A (da)
MY (1) MY174224A (da)
PH (1) PH12019502052A1 (da)
PL (1) PL3590942T3 (da)
PT (1) PT3590942T (da)
RS (1) RS62094B1 (da)
SG (1) SG11201908101YA (da)
SI (1) SI3590942T1 (da)
WO (1) WO2018161960A1 (da)
ZA (1) ZA201906252B (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016183266A1 (en) 2015-05-13 2016-11-17 Enanta Pharmaceuticals, Inc. Ehpatitis b antiviral agents
BR112018067964B1 (pt) 2016-03-07 2024-01-16 Enanta Pharmaceuticals, Inc Composto, composição farmacêutica que o compreende e uso do referido composto
CN110066278B (zh) 2017-06-01 2021-06-08 广东东阳光药业有限公司 稠合三环类化合物及其在药物中的应用
IL272941B2 (en) 2017-08-28 2023-03-01 Enanta Pharm Inc Antiviral agents for viral hepatitis b
US11058678B2 (en) 2018-01-22 2021-07-13 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2019169539A1 (en) * 2018-03-05 2019-09-12 Pharmaresources (Shanghai) Co., Ltd. Novel oxa-and aza-tricyclic 4-pyridone-3-carboxylic acid for treatment and prophylaxis of hepatitis b virus infection
US10729688B2 (en) 2018-03-29 2020-08-04 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
EP3846808A4 (en) * 2018-09-05 2022-08-17 Children's Medical Center Corporation PAPD5 INHIBITORS AND METHODS OF USE THEREOF
BR112021005091A2 (pt) 2018-09-21 2021-06-08 Enanta Pharmaceuticals, Inc. heterociclos funcionalizados como agentes antivirais
JP2022511378A (ja) 2018-09-30 2022-01-31 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 縮合四環系化合物および医薬品におけるそれらの使用
CN113271946A (zh) 2018-11-21 2021-08-17 英安塔制药有限公司 官能化杂环化合物作为抗病毒剂
US11236111B2 (en) 2019-06-03 2022-02-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2020247575A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
US11760755B2 (en) 2019-06-04 2023-09-19 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11738019B2 (en) 2019-07-11 2023-08-29 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US11236108B2 (en) 2019-09-17 2022-02-01 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
CA3151696A1 (en) * 2019-09-19 2021-03-25 Fujian Akeylink Biotechnology Co., Ltd. Crystal form of hepatitis b surface antigen inhibitor and application thereof
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
CN115515596A (zh) * 2020-05-15 2022-12-23 福建广生中霖生物科技有限公司 包含三并环类化合物的组合及其在制备治疗hbv药物中的应用
US20230183263A1 (en) * 2020-05-15 2023-06-15 Fujian Akeylink Biotechnology Co., Ltd. Combination for treating hepatitis b
WO2022112207A1 (en) * 2020-11-25 2022-06-02 F. Hoffmann-La Roche Ag Aromatic spiro ring amide derivatives for the treatment and prophylaxis of hepatitis b virus infection
WO2022152019A1 (zh) * 2021-01-15 2022-07-21 福建广生中霖生物科技有限公司 一种手性噁嗪类化合物的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130251647A1 (en) * 2011-09-20 2013-09-26 Basf Se Low molecular weight modulators of the cold menthol receptor trpm8 and use thereof
CN103450184A (zh) 2012-05-29 2013-12-18 上海壹志医药科技有限公司 斯氏紫堇碱衍生物的盐
SG11201605970QA (en) 2014-01-30 2016-08-30 Hoffmann La Roche Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
CN107207505B (zh) * 2015-02-11 2018-12-14 豪夫迈·罗氏有限公司 治疗和预防乙型肝炎病毒感染的 2-氧代-6,7-二氢苯并[a]喹嗪-3-甲酸衍生物
WO2017013046A1 (en) 2015-07-21 2017-01-26 F. Hoffmann-La Roche Ag Novel tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
WO2017017043A1 (en) * 2015-07-28 2017-02-02 F. Hoffmann-La Roche Ag Novel 6,7-dihydropyrido[2,1-a]phthalazin-2-ones for the treatment and prophylaxis of hepatitis b virus infection
CN107759585A (zh) 2016-07-29 2018-03-06 银杏树药业(苏州)有限公司 一种异喹啉类化合物及其药用组合物和作为抗病毒药物的应用

Also Published As

Publication number Publication date
US20200039995A1 (en) 2020-02-06
JP2020509075A (ja) 2020-03-26
HUE055170T2 (hu) 2021-11-29
PL3590942T3 (pl) 2021-12-13
BR112019018650B1 (pt) 2021-12-14
EP3590942B1 (en) 2021-06-09
LT3590942T (lt) 2021-07-12
CA3055442C (en) 2021-03-23
WO2018161960A1 (zh) 2018-09-13
PH12019502052A1 (en) 2020-07-06
EA038122B1 (ru) 2021-07-09
EP3590942A1 (en) 2020-01-08
AU2018232071A1 (en) 2019-10-17
KR102087397B1 (ko) 2020-03-11
EP3590942A4 (en) 2020-01-08
SG11201908101YA (en) 2019-10-30
IL269142B (en) 2020-07-30
CN109071564B (zh) 2019-08-27
SI3590942T1 (sl) 2021-11-30
US11008331B2 (en) 2021-05-18
MY174224A (en) 2020-03-23
BR112019018650A2 (pt) 2020-04-07
CA3055442A1 (en) 2018-09-13
EA038122B9 (ru) 2021-09-14
PT3590942T (pt) 2021-07-28
KR20190117799A (ko) 2019-10-16
MX2019010736A (es) 2019-11-05
RS62094B1 (sr) 2021-08-31
JP6783424B2 (ja) 2020-11-11
ZA201906252B (en) 2021-04-28
CN109071564A (zh) 2018-12-21
HRP20211331T1 (hr) 2021-11-26
AU2018232071B2 (en) 2021-07-08
EA201992082A1 (ru) 2020-02-12
ES2879930T3 (es) 2021-11-23

Similar Documents

Publication Publication Date Title
DK3590942T3 (da) Hepatitis B-virusoverfladeantigeninhibitor
DK3400291T3 (da) Manipuleret virus
CL2019000278A1 (es) Agentes rnai para infección con virus de hepatitis b.
ES2981193T3 (es) Anticuerpos antisirpalpha
DK3512850T3 (da) Inhibitorer af menin-mll-interaktionen
DK3468966T3 (da) Inhibitorer af menin-mll-interaktionen
DK3371316T3 (da) Vacciner mod hepatitis b-virus
DK3221346T3 (da) Antistoffer omfattende modificerede konstante områder af tungkæden
DK3606961T3 (da) Garp-tgf-beta-antistoffer
EP3632914A4 (en) HEPATITIS B VIRUS SURFACE ANTIGEN INHIBITOR
DK3898668T5 (da) Antistoffer der neutraliserer hepatitis b virus og anvendelser deraf
SG11201605691VA (en) Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
DK3946179T3 (da) Stomiposer
DK3737403T5 (da) Modificerede adenovira
DK3463001T3 (da) Kogegrej
DK3484921T3 (da) Anti-IL-22R antistoffer
DE112017000535T8 (de) Welle
DK3274340T3 (da) Hæmmere af hepatitis c-viruspolymerase
DK3263590T3 (da) Fiskevirus
DK3599479T3 (da) Projektildetektering
HK1245775A1 (zh) 作為丙型肝炎病毒抑制劑的鹽
EP3473639A4 (en) HEPATITIS-C VIRUS INHIBITOR AND APPLICATION
DK3448420T3 (da) Anti-notch3-antistof
DE112019006370A5 (de) Strahlungsemittierendes bauelement
DE112019004670A5 (de) Strahlungsemittierendes bauelement